GLYCOMIMETICS INC
For the period ended Dec 31, 2023. Filed Mar 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 27, 2024
CBIO$13.65+0.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
| | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| · · Year Ended December 31, | |||||||||
| · · 2023 · · 2022 · · 2021 | |||||||||
| Operating activities · · · · · · · | |||||||||
| Net loss | | $(36,899,420) | | $(46,688,802) | | $(63,427,437) | |||
| Adjustments to reconcile net loss to net cash used in operating activities: | | | | | | | | | |
| Depreciation | | 153,301 | | 207,145 | | 264,600 | |||
| Loss on disposal of assets | | | 8,627 | | | 3,498 | | | 2,174 |
| Non-cash lease expense | | | 856,238 | | | 825,011 | | | 749,039 |
| Issuance of common stock for services | | | 36,000 | | | — | | | — |
| Stock-based compensation | | 3,524,476 | | 3,857,580 | | 6,087,286 | |||
| Changes in assets and liabilities: | | | | | | | | | |
| Prepaid expenses and other current assets | | 846,182 | | (2,310,282) | | 704,524 | |||
| Prepaid research and development expenses | | | (553,737) | | | 1,510,607 | | | — |
| Accounts payable | | (102,076) | | (1,137,424) | | 17,676 | |||
| Accrued expenses | | | (1,766,449) | | | (1,723,362) | | | (988,842) |
| Lease liabilities | | (983,045) | | (1,001,459) | | (898,550) | |||
| Net cash used in operating activities | | (34,879,903) | | (46,457,488) | | (57,489,530) | |||
| | | | | | | | | | |
| Investing activities | | | | | | | | | |
| Purchases of property and equipment | | (21,394) | | (84,191) | | (14,943) | |||
| Net cash used in investing activities | | (21,394) | | (84,191) | | (14,943) | |||
| | | | | | | | | | |
| Financing activities | | | | | | | | | |
| Proceeds from issuance of common stock, net of issuance costs | | 28,707,011 | | 4,157,408 | | 10,699,317 | |||
| Proceeds from exercise of stock options | | 116,497 | | — | | 25,029 | |||
| Net cash provided by financing activities | | 28,823,508 | | 4,157,408 | | 10,724,346 | |||
| Net change in cash and cash equivalents | | (6,077,789) | | (42,384,271) | | | (46,780,127) | ||
| Cash and cash equivalents, beginning of period | | 47,870,619 | | 90,254,890 | | 137,035,017 | |||
| Cash and cash equivalents, end of period | | $41,792,830 | | $47,870,619 | | $90,254,890 | |||
| | | | | | | | | | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.